Skip to content
10-Q

Quarterly Report

Ensysce Biosciences, Inc. ENSC ENSCW

0001493152-26-023811

← back to feed
Filed
May 15, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 14.69M sh
Shares Diluted Q1 2026 · Mar 31, 2026 6.84M sh
Shares Diluted Q1 2026 · Mar 31, 2025 1.4M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.5M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.71M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $745.48K
Cash And Equivalents Q1 2026 · Dec 31, 2025 $4.31M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$340.04K
Stockholders Equity Q1 2026 · Dec 31, 2025 $3.21M
Current Liabilities Q1 2026 · Mar 31, 2026 $2.84M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.57M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.84M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.57M
Current Assets Q1 2026 · Mar 31, 2026 $2.01M
Current Assets Q1 2026 · Dec 31, 2025 $7.25M
Total Assets Q1 2026 · Mar 31, 2026 $2.17M
Total Assets Q1 2026 · Dec 31, 2025 $7.45M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.52
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.39
Eps Basic Q1 2026 · Mar 31, 2026 −$0.52
Eps Basic Q1 2026 · Mar 31, 2025 −$1.39
Rd Expense Q1 2026 · Mar 31, 2026 $3.35M
Rd Expense Q1 2026 · Mar 31, 2025 $1.89M
Operating Income Q1 2026 · Mar 31, 2026 −$3.56M
Operating Income Q1 2026 · Mar 31, 2025 −$1.97M
Revenue Q1 2026 · Mar 31, 2026 $961K
Revenue Q1 2026 · Mar 31, 2025 $1.32M